cdx-0159
mAbexperimental
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04146129)
Timeline
Indications
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095266 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266402 | Phase 3 | Dec 31, 2025 | Celldex Therapeutics |
| NCT07256392 | Phase 3 | Nov 25, 2025 | Celldex Therapeutics |
| NCT06727552 | Phase 2 | Dec 31, 2024 | Celldex Therapeutics |
| NCT06455202 | Phase 3 | Jul 19, 2024 | Celldex Therapeutics |
| NCT06445023 | Phase 3 | Jul 11, 2024 | Celldex Therapeutics |
| NCT06366750 | Phase 2 | Apr 12, 2024 | Celldex Therapeutics |
| NCT05774184 | Phase 2 | Jun 1, 2023 | Celldex Therapeutics |
| NCT05405660 | Phase 2 | Jun 28, 2022 | Celldex Therapeutics |
| NCT05368285 | Phase 2 | May 19, 2022 | Celldex Therapeutics |
| NCT04944862 | Phase 1 | Oct 31, 2021 | Celldex Therapeutics |
| NCT05031624 | Phase 1 | Aug 30, 2021 | Celldex Therapeutics |
| NCT04548869 | Phase 1 | Nov 24, 2020 | Celldex Therapeutics |
| NCT04538794 | Phase 1 | Sep 24, 2020 | Celldex Therapeutics |
| NCT04146129 | Phase 1 | Nov 30, 2019 | Celldex Therapeutics |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 14 | 14 | 3 | 2019 |
1 organizations
Page 1 / 1